Search Press releases Keywords From To 10 Nov 2023 UCB Presents New Five-Year Data on BIMZELX[®]▼(bimekizumab) in Ankylosing Spondylitis at ACR Convergence 2023 Read More 9 Nov 2023 UCB successfully completes its offer to the public of fixed rate notes and decides to early terminate the subscription period Read More 7 Nov 2023 UCB launches an offer to the public of 6-year 5.20% fixed rate notes in Belgium and in Luxembourg Read More 1 Nov 2023 UCB presents latest data from generalized myasthenia gravis portfolio at 2023 AANEM Annual Meeting and MGFA Scientific Session Read More 18 Oct 2023 BIMZELX[®] Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis Read More 17 Oct 2023 UCB announces U.S. FDA approval of ZILBRYSQ[®] (zilucoplan) for the treatment of adults with generalized myasthenia gravis Read More Pagination First page Previous page Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
